A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for ...

Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

Testing for C. difficile is indicated in patients with diarrhea, especially after antibiotic use or healthcare exposure. Early testing facilitates prompt diagnosis and management, influencing ...